Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25871834 | 0.88 | SMN1; SMN2 (0.35) | ALDH1A1MAPTL3MBTL1HPGDKDM4E | |
| SCHEMBL115839 | 0.88 | SMN1; SMN2 (0.35) | ALDH1A1MAPTL3MBTL1HPGDKDM4E | |
| SCHEMBL29936639 | 0.88 | SMN1; SMN2 (0.35) | ALDH1A1MAPTL3MBTL1HPGDKDM4E | |
| SCHEMBL29813282 | 0.79 | MEN1 (0.31) | MAPT | |
| SCHEMBL5460805 | 0.75 | TAS1R3 (0.38) | ALDH1A1MAPTHPGDTAS1R3TAS1R1 | |
| SCHEMBL24809655 | 0.74 | TSHR (0.32) | MAPTTSHR | |
| SCHEMBL23182669 | 0.73 | TSHR (0.31) | MAPTTSHR | |
| SCHEMBL25985347 | 0.71 | TAS1R3 (0.33) | MAPTHPGDTAS1R3TAS1R1KDM4E | |
| SCHEMBL9999441 | 0.69 | LMNA (0.34) | ALDH1A1MAPTHPGDSMN1; SMN2LMNA | |
| SCHEMBL1753958 | 0.69 | HTT (0.52) | ALDH1A1MAPTL3MBTL1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286932-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | NEUROCRINE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230255942-A1 | CRF1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | QUOTIENT SCIENCES LIMITED (GB) | 2023-08-17 | — | — | US | disclosed |
| EP-2424848-B1 | Process for the preparation of [4-(2-chloro-4-methoxy-5-methylphenyl)-5-methyl-thiazol-2-yl]-[2-cyclopropyl-1-(3-fluoro-4-methylphenyl)-ethyl]-amine | SANOFI SA (FR) | 2013-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255942-A1 | CRF1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | CRHR1, MC2R, CRHR2 | ALDH1A1 802/4885MAPT 4436/4885ELANE 1726/4885 |
| US-20230286932-A1 | SYNTHETIC METHODS FOR PREPARATION OF 4-(2-CHLORO-4-METHOXY-5-METHYLPHENYL)-N-[(1S)-2-CYCLOPROPYL-1-(3-FLUORO-4-METHYLPHENYL)ETHYL]-5-METHYL-N-PROP-2-YNYL-1,3-THIAZOL-2-AMINE | CYP21A2, NR5A1, HSD3B1 | ALDH1A1 700/4885MAPT 3081/4885ELANE 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.